viewSeelos Therapeutics

Seelos Therapeutics shares push higher as it reveals patent news for SLS-005 drug

The group is focused on advancing therapeutics to address unmet medical needs for central nervous system disorders and other rare conditions

Seelos Therapeutics -
Seelos has received a 'Notice of Allowance' from the United States Patent and Trademark Office for the drug candidate, known as trehalose

Seelos Therapeutics Inc (NASDAQ:SEEL) shares advanced on Monday as the biopharma group reported on patent news for its SLS-005 drug, known as trehalose.

The group is focused on advancing various therapeutics to address unmet medical needs for central nervous system (CNS) disorders and other rare conditions.

READ: Seelos Therapeutics shares gain as it receives Orphan Drug designation for SLS-005

In a brief statement, Seelos said it had received a 'Notice of Allowance' from the United States Patent and Trademark Office (USPTO) to allow claims, which cover the composition of matter and method of use for trehalose (SLS-005) for a number of conditions.

The conditions are Spinal and bulbar muscular atrophy (SBMA); Dentatombral-pallidoluysian atrophy (DRPLA), Pick's disease, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), frontotemporal dementia, or parkinsonism linked to chromosome 17 (FTDP-17).

Monday's share price gain came after a strong advance on April 30 when Seelos revealed it had received Orphan Drug Designation from the US Food & Drug Administration (FDA) for SLS-005 as a treatment for patients with Type A and B versions of Sanfilippo syndrome, a childhood disorder that triggers fatal brain damage. The designation offers a number of advantages for firms, including access to various incentives like tax credits for qualified clinical testing.

SLS-005 has already been granted ODD status by the FDA, as well as the European Medicines Agency (EMA), for the treatment of Spinocerebellar Ataxia Type 3 and Oculopharyngeal Muscular Dystrophy.

New York-based Seelos said it has also submitted an application to the FDA requesting Rare Pediatric Disease Designation for SLS-005 and is awaiting the regulator’s response.

Seelos shares in New York were nearly 2% higher in early deals at $0.63.

Contact the author at [email protected]

Quick facts: Seelos Therapeutics

Price: 1.03 USD

Market: NASDAQ
Market Cap: $55.03 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...


Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York. Dr. Mehra says since listing on the exchange in January, the small company has achieved an...

on 08/12/2019

2 min read